Modern aspects of pathogenesis of comorbidity of non-alcoholic fatty liver disease and hypertension in the presence or absence of сhronic kidney disease

Posted on by adminLeave a comment

Prof. K. Prosolenko, ass. К. Lapshyna, V. Ryabuha  

Kharkiv National Medical University. 

Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” 

The article presents the main aspects of the pathogenesis of comorbidity of non-alcoholic fatty liver disease and hypertension. These diseases are very often presented as comorbidities in a large number of patients and can independently impair renal function. According to the literature and the results of our own research, the role of insulin resistance, disorders of lipid and carbohydrate metabolism, cytokine imbalance, disorders of the antioxidant defense system in the pathogenesis of this comorbidity was analyzed. The effect of hypoadictinemia and increased blood levels of fetuin-A and cytokeratin-18 on this comorbidity was also assessed. The independent effect of non-alcoholic fatty liver disease on renal function, arterial stiffness and the occurrence of diastolic heart function was analyzed. The interaction between non-alcoholic fatty liver disease and hypertension depending on the presence of chronic kidney disease was also evaluated.  

Key words: nonalcoholic fatty liver disease, hypertension, pathogenesis, comorbidity, renal impairment. 

https://doi.org/10.15407/internalmed2022.01.055 

Download.PDF (ukr) 

For cite: 

Просоленко, К.О. Сучасні аспекти патогенезу коморбідності неалкогольної жирової хвороби печінки та артеріальної гіпертензії при наявності або відсутності хронічної хвороби нирок / К.О. Просоленко, К.А. Лапшина, В.В. Рябуха // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2022. – № 1. – С. 55-63. doi:  10.15407/internalmed2022.01.055   

Prosolenko KO, Lapshyna KA, Ryabuha VV. Suchasni aspekty patohenezu komorbidnosti nealkoholnoi zhyrovoi khvoroby pechinky ta arterialnoi hipertenzii pry naiavnosti abo vidsutnosti khronichnoi khvoroby nyrok. [Modern aspects of pathogenesis of comorbidity of non-alcoholic fatty liver disease and hypertension in the presence or absence of сhronic kidney disease]. Shidnoevr. z. vnutr. simejnoi med. 2022;1:55-63. Ukrainian. doi: 10.15407/internalmed2022.01.055   

References: 

  1. Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day C, Eguchi Y, Geier A, Kondili L, Kroy D, Lazarus J, Loomba R, Manns M, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg J, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology. 2018;69(4):896-904. http://dx.doi.org/10.1016/j.jhep.2018.05.036
  2. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103(1):22-7. doi: 10.1097/TP.0000000000002484.
  3. Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with metaanalysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696-703. doi: 10.1111/apt.14937
  4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip G, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(12):2284-2309. http://dx.doi.org/10.1097/hjh.0000000000001961
  5. Perazzo H, Poynard T, Dufour JF The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clin Liver Dis. 2014;18(1):233-48. https://doi.org/10.1016/j.cld.2013.09.014
  6. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013
  7. Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol. 2018;31(3):296—304. https://doi.org/10.20524/aog.2018.0248
  8. Aneni E, Oni E, Martin S, Blaha M, Agatston A, Feldman T, Veledar E, Conçeicao R, Carvalho J, Santos R, Nasir K. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. Journal of Hypertension. 2015;33(6):1207-1214. http://dx.doi.org/10.1097/hjh.0000000000000532
  9. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology. 2018;68(2):268-279. http://dx.doi.org/10.1016/j.jhep.2017.09.003
  10. Hribeniuk OV. Znachennia komorbidnoi nealkoholnoi zhyrovoi khvoroby pechinky u modyfikatsii perebihu hipertonichnoi khvoroby ta mozhlyvosti optymizatsii medykamentoznoho likuvannia [dysertatsiia]. Vinnytsia; 2018. 301 р. Ukrainian
  11. Ilan Y. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2016;310(11):G1102-G1117. http://dx.doi.org/10.1152/ajpgi.00095.2016
  12. Prosolenko KO. Antropometrychni ta deiaki kliniko-metabolichni pokaznyky u patsiientiv z komorbidnistiu nealkoholnoi zhyrovoi khvoroby pechinky ta hipertonichnoi khvoroby. Suchasna hastroenterolohiia. 2015;(6):45-52. Ukrainian
  13. Byrne C, Targher G. NAFLD: A multisystem disease. Journal of Hepatology. 2015;62(1):S47-S64. http://dx.doi.org/10.1016/j.jhep.2014.12.012
  14. Perseghin G, Manzoni G, Grassi G. Hypertension and hepatic triglycerides content. Journal of Hypertension. 2017;35(4):715-717. http://dx.doi.org/10.1097/hjh.0000000000001290
  15. Luo K, Bian J, Wang Q, Wang J, Chen F, Li H, Jin D. Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease. Turk J Gastroenterol. 2019;30(7):611-5. doi: 10.5152/tjg.2019.18343
  16. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785—801. doi: 10.1016/j. jhep.2020.01.013
  17. Ivanov DD. Lekcii po nefrologii. Doneck: Izdatel’ Zaslavskij A.Ju.; 2011. 196 p. Russian
  18. Montgomery MK, Turner N. Mitochondrial dysfunction and insulin resistance: an update. Endocr. Connect. 2015;4(1):R1— R15. doi:10.1530/EC-14-0092PMCID: PMC4261703
  19. Dedov II, Mel’nichenko GA. Ozhirenie: jetiologija, patogenez, klinicheskie aspekty. M.: Med. inform. Agentstvo; 2006. 456 s. Russian
  20. Bratus’ VV, Talaeva TV, Shumakov VA. Ozhirenie, insulinorezistentnost’, metabolicheskij sindrom: fundamental’nye i klinicheskie aspekty. Kiev: Chetverta hvilja; 2009. 416 p. Russian
  21. Kumar S, O’Rahylly S. Insulin Resistance. Insulin action and its disturbances in disease. Chichester: John Wiley & Sons, Ltd; 2005. 616 p. https://doi.org/10.1002/0470011327
  22. Shalimova A. Heart and vascular remodeling in essential hypertension and type 2 diabetes is dependent on genetic polymorphisms. Vessel Plus. 2017;1(2): 84-90. http://dx.doi.org/10.20517/2574-1209.2016.08
  23. Bulatova IA, Shhjokotova AP, Suzdal’ceva KN, Shhjokotov VV, Ulitina PV, Zhizhilev EV. Superoksiddismutaza i glutationreduktaza pri hronicheskom gepatite s i nealkogol’noj zhirovoj bolezni pecheni. Fundamental’nye issledovanija. 20147(3):455 — 9. Russian
  24. Ayala A, Muñoz MF, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxidative Medicine and Cellular Longevity. 2014;2014:360438. doi: 10.1155/2014/360438
  25. Promenasheva TE, Kolesnichenko LS, Kozlova NM. Rol’ oksidativnogo stressa i glutationa v patogeneze nealkogol’noj zhirovoj bolezni pecheni. Vestnik RNCB SO RAMN. 2014;(99):80-3. Russian
  26. Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47(11):869-80. doi: 10.3109/10715762.2013.837577
  27. Al-Serri A, Anstee Q, Valenti L, Nobili V, Leathart J, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day C, Daly A. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology. 2012;56(2):448-454. http://dx.doi.org/10.1016/j.jhep.2011.05.029
  28. Prosolenko KO. Pokaznyky oksydatyvnoho stresu na antyoksydantnoi aktyvnosti pry komorbidnosti nealkoholnoi zhyrovoi khvoroby pechinky ta arterialnoi hipertenzii. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2020;5(1):179-86. Ukrainian
  29. Wellen K, Hotamisligil G. Obesity-induced inflammatory changes in adipose tissue. Journal of Clinical Investigation. 2003;112(12):1785-1788. http://dx.doi.org/10.1172/jci20514
  30. Fediv OI, Tsyntar TP, Ushakov VI. Tsytokinovyi profil i vmist adypokiniv u khvorykh na nealkoholnyi steatohepatyt, poiednanyi iz khronichnym obstruktyvnym zakhvoriuvanniam lehen. Bukovynskyi medychnyi visnyk. 2017;21(3):108-13. Ukrainian
  31. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46—54. https://doi.org/10.1002/hep.20280
  32. Serebrjakova OE. Vzaimosvjaz’ polimorfizma gena faktora nekroza opuholi al’fa s riskom razvitija metabolicheskogo sindroma i ateroskleroza [avtoreferat]. Moskva; 2014. 25 p. Russian
  33. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 2008;27(7):833—9. doi: 10.1007/s10067-007-0803y
  34. Dschietzig T, Brecht A, Bartsch C, Baumann G, Stangl K, Alexiou K. Relaxin improves TNF-α-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovascular Research. 2012;95 (1):97-107. https://doi.org/10.1093/cvr/cvs149
  35. Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Rev Gastroenterol Hepatol. 2015;9(8):1055-67. doi: 10.1586/17474124.2015.1056156
  36. Prosolenko KO. Prozapalnyi status pry nealkoholnii zhyrovii khvorobi pechinky ta pry yii komorbidnosti z arterialnoiu hipertenziiu. Ukrainskyi terapevtychnyi zhurnal. 2019;(4):57-62. Ukrainian https://doi.org/10.30978/UTJ2019-4-57
  37. Mian MO, Paradis P, Schiffrin EL. Innate immunity in hypertension. Curr Hypertens Rep. 2014;16(2):413. https://doi.org/10.1007/s11906-013-0413-9
  38. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23(5):376-83. doi: 10.1053/euhj.2001.2805
  39. Johnson RJ, Lanaspa MA, Gabriela Sánchez-Lozada L, Rodriguez-Iturbe B. The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics. Am J Physiol Renal Physiol. 2015; 308(3):F167-78. https://doi.org/10.1152/ajprenal.00503.2014
  40. Prosolenko KO. Nyrkova funktsiia pry nealkoholnii zhyrovii khvorobi pechinky ta pry yii komorbidnosti z arterialnoiu hipertenziiu. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2019;4(6):186-93. Ukrainian https://doi.org/10.26693/jmbs04.06.186
  41. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6): 1138-53. doi: 10.1136/gutjnl-2017-313884.
  42. Babak OYa, Prosolenko КО. Markers of liver damage in comorbidity of non-alcoholic liver disease and hypertension. East European Scientific Journal. 2019:(12):39-45.
  43. Baroncini LA, de Castro Sylvestre L, Filho RP. Carotid intima-media thickness and carotid plaque represent different adaptive responses to traditional cardiovascular risk factors. Int J Cardiol Heart Vasc. 2015;9:48-51. https://doi.org/10.1016/j.ijcha.2015.08.003
  44. Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and metaanalysis. Eur J Gastroenterol Hepatol. 2017;29(9):e28-e35. doi: 10.1097/MEG.0000000000000909
  45. Yu XY, Zhao Y, Song XX, Song ZY. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. J Zhejiang Univ Sci B. 2014;15(10):879-87. doi: 10.1631/jzus.B1400028
  46. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology. 2015;21(22):6820-34. doi: 10.1016/j.metabol.2017.02.014
  47. Guarneri M, Geraci C, Incalcaterra F, Arsena R, Mulè G, Vaccaro F, Luna C, Cerasola G, Cottone S. Subclinical atherosclerosis and fetuin-A plasma levels in essential hypertensive patients. Hypertension Research. 2012;36(2):129-133. http://dx.doi.org/10.1038/hr.2012.136
  48. Senturk O, Kocaman O, Hulagu S, Sahin T, Aygun C, Konduk T, Celebi A. Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern Med J. 2008;38:183—9. https://doi.org/10.1111/j.1445-5994.2007.01481.x
  49. Mohammadi A, Sedani HH, Ghasemi-Rad M. Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. Vasc Health Risk Manag. 2011;7:661—5. https://doi.org/10.2147/VHRM.S26011
  50. Thakur M, Sharma S, Kumar A, Bhatt S, Luthra K, Guleria R, Pandey R, Vikram N. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012;223(2):507-511. http://dx.doi.org/10.1016/j.atherosclerosis.2012.06.005
  51. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci O, Agladioglu K, Yeniova A, Nazligul Y, Ertugrul D. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology. 2013;25(2):147-151. http://dx.doi.org/10.1097/meg.0b013e32835a58b1
  52. Sciacqua A, Perticone M, Miceli S, Laino I, Tassone E, Grembiale R, Andreozzi F, Sesti G, Perticone F. Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutrition, Metabolism and Cardiovascular Diseases. 2011;21(7):485-491. http://dx.doi.org/10.1016/j.numecd.2009.11.015
  53. Santaniemi M, Kesäniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol. 2006;155(5):745-50. doi: 10.1530/ eje.1.02287
  54. Feldman A, Eder S, Felder T, Kedenko L, Paulweber B, Stadlmayr A, Huber-Schönauer U, Niederseer D, Stickel F, Auer S, Haschke-Becher E, Patsch W, Datz C, Aigner E. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. American Journal of Gastroenterology. 2017;112(1):102-110. http://dx.doi.org/10.1038/ajg.2016.318
  55. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci. 2017;18(8):1649. doi: 10.3390/ijms18081649
  56. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Möhlig M, Pfeiffer A, Luft F, Sharma A. Association Between Adiponectin and Mediators of Inflammation in Obese Women. Diabetes. 2003;52(4):942-947. http://dx.doi.org/10.2337/diabetes.52.4.942
  57. Jensen MD. Adipose tissue as endocrine organ: implication of its distri-bution on free fatty acid metabolism. Eur Heart J. 2006;8(Suppl В):В13—В19. https://doi.org/10.1093/eurheartj/sul003
  58. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930- 5. doi: 10.1210/jcem.86.5.7463
  59. Qi Y, Takahashi N, Hileman S, Patel H, Berg A, Pajvani U, Scherer P, Ahima R. Adiponectin acts in the brain to decrease body weight. Nature Medicine. 2004;10(5):524-529. http://dx.doi.org/10.1038/nm1029
  60. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25(6):971-6. doi: 10.2337/diacare.25.6.971
  61. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep. 2003;3(3):207-13. doi: 10.1007/s11892-003-0065-2
  62. Yoo HJ, Choi KM. Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J. 2015;39(1):10-5. doi: 10.4093/dmj.2015.39.1.10
  63. Zhao D, Liu H. Adipose tissue dysfunction and the pathogenesis of metabolic syndrome. World J Hypertens. 2013;3(3):18- 26. doi: 10.5494/wjh.v3.i3.18
  64. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):352-9. doi: 10.5507/ bp.2015.018
  65. Lebensztejn DM, Białokoz-Kalinowska I, Kłusek-Oksiuta M, Tarasów E, Wojtkowska M, Kaczmarski M. Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease. Adv Med Sci. 2014;59(1):81-4. https://doi.org/10.1016/j.advms.2013.08.003
  66. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2012;166(3):503- 10. doi: 10.1530/EJE-11-0864
  67. Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y, Wu Y, Chen Y, Wang W, Li X, Ning G. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011;216(1):180-186. http://dx.doi.org/10.1016/j.atherosclerosis.2011.01.020
  68. Cui Z, Xuan R, Yang Y. Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population Oncotarget. 2017;8(63):107149—56. https://doi.org/10.18632/oncotarget.22361
  69. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3(3):e1765. doi: 10.1371/journal.pone.0001765
  70. Hermans M, Brandenburg V, Ketteler M, Kooman J, van der Sande F, Boeschoten E, Leunissen K, Krediet R, Dekker F. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney International. 2007;72(2):202-207. http://dx.doi.org/10.1038/sj.ki.5002178
  71. Ix JH, Sharma K. Mechanism linking obesity, chronic kidney disease and fatty liver disease: the roles of fetuin-A, adiponectin and AMPK. J Am Soc Nephrol. 2010;21(3):406-12. https://doi.org/10.1681/ASN.2009080820
  72. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93(11): 4479-85. https://doi.org/10.1210/jc.2008-1505
  73. Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010;95(11):4877-81. doi: 10.1210/jc.2010-0148
  74. Lavebratt C, Wahlqvist S, Nordfors L, Hoffstedt J, Arner P. AHSG variant is associated with leaness among Swedish men. Hum Genet. 2005;117(1):54-60. https://doi.org/10.1007/s00439-005-1286-z
  75. Dogru T, Genc H, Tapan S, Aslan F, Ercin C, Ors F, Kara M, Sertoglu E, Karslioglu Y, Bagci S, Kurt İ, Sonmez A. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clinical Endocrinology. 2013;78(5):712-717. http://dx.doi.org/10.1111/j.1365-2265.2012.04460.x
  76. Singh M, Sharma PK, Garg VK, Mondal SC, Singh AK, Kumar N. Role of fetuin-A in atherosclerosis associated with diabetic patients. J Pharm Pharmacol. 2012;64(12):1703-8. doi: 10.1111/j.2042-7158.2012.01561.x
  77. Prosolenko KO. Otsinka pokaznykiv fetuinu-A u patsiientiv z komorbidnostiu nealkoholnoi zhyrovoi khvoroby pechinky ta arterialnoi hipertenzii. Skhidno-yevropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny. 2019;(2):83-9. Ukrainian
  78. Kanda T, Matsuoka S, Yamazaki M. Apoptosis and nonalcoholic fatty liver diseases. World J Gastroenterol. 2018;24(25): 2661-72. doi: 10.3748/wjg.v24.i25.2661
  79. Yilmaz Y, Alahdab Y, Yonal O, Kurt R, Kedrah A, Celikel C, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism. 2010;59(9):1327-1330. http://dx.doi.org/10.1016/j.metabol.2009.12.012
  80. Tamimi T, Elgouhari H, Alkhouri N, Yerian L, Berk M, Lopez R, Schauer P, Zein N, Feldstein A. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. Journal of Hepatology. 2011;54(6):1224-1229. http://dx.doi.org/10.1016/j.jhep.2010.08.023
  81. Natale F, Tedesco MA. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr. 2009;10:549- 55. https://doi.org/10.1093/ejechocard/jep002
  82. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98—108.
  83. VanWagner L, Wilcox J, Ning H, Lewis C, Carr J, Rinella M, Shah S, Lima J, Lloyd‐Jones D. Longitudinal Association of Non‐Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. Journal of the American Heart Association. 2020;9(4):. http://dx.doi.org/10.1161/jaha.119.014279
  84. Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Saitoh S, Takeishi Y. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Failure. 2017;5(2):262-270. http://dx.doi.org/10.1002/ehf2.12222
  85. Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, Chiesa C. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59(2):461—70. doi: 10.1002/hep.26610